INV043 DRAMATICALLY IMPROVED IMMUNE CHECKPOINT INHIBITOR EFFECTIVENESS WHEN USED IN COMBINATION, ACHIEVING ~80% TUMOUR CONTROL IN PRECLINICAL STUDIESHighlights:
Topically applied INV043 in combination with an immune checkpoint inhibitor (ICI) resulted in ~80% of subjects being tumour-free. The study was conducted by Peter Mac using immune competent anal squamous cell carcinoma (ASCC) in vivo models
ICIs, the standard of care for the treatment of several cancers, are a class of immunotherapy drug. Despite widespread clinical use as a monotherapy, ICI effectiveness is typically limited to a small proportion of patients
Results support previous findings by Hudson Institute using intratumorally administered INV043 in combination with ICIs on another cancer type (triple negative breast cancer)
Opens additional treatment options for upcoming clinical trial programs that span multiple cancers ASCC has potential to be designated as an orphan indication – leading to an expedited regulatory approval process
The findings reinforce the potential for collaboration partnerships using combination therapies to extend the patent life of blockbuster ICIs
Global ICI market forecast to grow at 16.8% CAGR to reach US$189 billion by 20321
IVX Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)